8-K: Virios Therapeutics and Wex Pharmaceuticals Combine to Form Dogwood Therapeutics, Securing $19.5 Million Financing

Virios Therapeutics and Wex Pharmaceuticals have merged to create Dogwood Therapeutics, a company focused on developing treatments for pain and viral-related diseases, backed by a $19.5 million financing.

Summary

• Virios Therapeutics and Wex Pharmaceuticals have combined to form Dogwood Therapeutics, which will trade on the Nasdaq under the ticker DWTX starting October 9, 2024.
• The merger includes a $19.5 million debt financing from an affiliate of CK Life Sciences Intl., (Holdings) Inc., with $16.5 million at closing and an additional $3 million in 1Q25.
• Dogwood Therapeutics will focus on three assets: Halneuron for chemotherapy-induced neuropathic pain (CINP), IMC-1 for fibromyalgia (FM), and IMC-2 for Long-COVID.
• Existing Virios stockholders will receive a contingent value right (CVR) tied to potential milestone payments from future partnerships for IMC-1 and IMC-2.
• A 25-for-1 reverse stock split will be effective on October 9, 2024, resulting in 1,110,317 outstanding shares of common stock prior to the issuance of shares pursuant to the share exchange agreement.

Sentiment

Score: 7

Explanation: The document is generally positive, highlighting the strategic benefits of the merger, the potential of the pipeline, and the secured financing. However, the dilution of existing shareholders and the reliance on a single lender temper the overall sentiment.

Positives

• The merger expands the pipeline with a novel program, Halneuron, a potential first-in-class non-opioid pain treatment.
• The financing provides working capital to fund operations through key milestones, including the Halneuron Phase 2b interim data readout.
• The CVR provides upside opportunity for existing Virios stockholders to receive future cash payments from potential licensing partnerships.
• The combined company will be led by an experienced management team with a track record of developing and commercializing pain medicines.
• Halneuron has received Fast Track Designation from the FDA for the treatment of CINP.

Negatives

• The merger results in a significant dilution of existing Virios shareholders, with Sealbond receiving approximately 94% of the combined company on a fully diluted basis.
• The CVR is non-transferable and its value is contingent on future partnering transactions, which may not occur.
• The company is reliant on a single lender for its financing.

Risks

• The success of the combined company is dependent on the clinical development of its three assets, which are subject to inherent risks and uncertainties.
• The company is reliant on a single lender for its financing.
• The CVR is non-transferable and its value is contingent on future partnering transactions, which may not occur.
• The company is subject to the risks associated with the pharmaceutical industry, including regulatory approvals, clinical trial results, and market competition.

Future Outlook

The company expects the financing to fund operations through key milestones, including the Halneuron Phase 2b interim data readout in 2H25 and the IMC-2 Long-COVID Phase 2a study results in early 4Q24. The company is also exploring partnerships for IMC-1 to execute the Phase 3 FM program.

Management Comments

• This transaction represents our deep commitment to delivering value to stockholders by expanding our pipeline with a synergistic, novel program while also providing the upside opportunity for existing Virios stockholders to receive future cash payments through CVRs for potential licensing partnerships relating to IMC-1 and IMC-2, said Greg Duncan, Chief Executive Officer.
• With the anticipated funding and an accomplished management team, we believe Dogwood is well-positioned to advance its programs by leveraging its FDA Fast Track designations for IMC-1 and Halneuron.
• Both preclinical and clinical data support sodium channel inhibition as a non-opioid approach to treat CINP, which can be a long-term condition affecting approximately one in three patients following chemotherapy, said Mike Gendreau, M.D., PhD, Chief Medical Officer.
• Halneuron is a voltage-gated sodium channel inhibitor that modulates transmission of pain signals, a mechanism proven to treat pain, with the potential to serve as a non-opioid treatment for both acute and chronic pain, including CINP, for which there are currently no FDA approved treatments.

Industry Context

The merger reflects a trend in the pharmaceutical industry towards consolidation and pipeline expansion. The focus on non-opioid pain treatments aligns with the growing need for alternatives to opioids in pain management.

Comparison to Industry Standards

• The focus on non-opioid pain treatments aligns with the growing need for alternatives to opioids in pain management, a trend seen across the pharmaceutical industry.
• The company's pipeline includes Halneuron, a novel sodium channel inhibitor, which is a different approach to pain management compared to traditional treatments.
• The company's focus on viral-related diseases is a unique approach compared to other companies in the pain management space.
• The company's pipeline includes IMC-1 and IMC-2, which are combination antiviral treatments, a novel approach to treating fibromyalgia and Long-COVID, respectively.
• The company's approach to Long-COVID is unique, as it focuses on the viral component of the disease, rather than just the symptoms.

Management Changes

Corporate Governance

Related Party Transactions

• The company entered into a loan agreement with an affiliate of CKLS for a cash investment of $19.5 million.
• Sealbond, an indirect wholly-owned subsidiary of CKLS, will receive an aggregate of 211,383 shares of common stock and 2,108.3854 shares of non-voting convertible preferred stock in the Combination.

Stakeholder Impact

• Existing Virios stockholders will receive a CVR tied to potential milestone payments from future partnerships for IMC-1 and IMC-2.
• The merger expands the pipeline with a novel program, Halneuron, a potential first-in-class non-opioid pain treatment.
• The financing provides working capital to fund operations through key milestones, including the Halneuron Phase 2b interim data readout.
• The combined company will be led by an experienced management team with a track record of developing and commercializing pain medicines.

Next Steps

• The company will seek stockholder approval for the conversion of the Preferred Stock.
• The company will advance the clinical development of Halneuron, IMC-1, and IMC-2.
• The company will explore partnerships for IMC-1 to execute the Phase 3 FM program.
• The company will release topline data from the IMC-2 Long-COVID Phase 2a study in early 4Q24.
• The company will release interim data from the Halneuron Phase 2b CINP study in 2H25.

Key Dates

Keywords

Dogwood Therapeutics, Virios Therapeutics, Wex Pharmaceuticals, Halneuron, IMC-1, IMC-2, CINP, Fibromyalgia, Long-COVID, Reverse Stock Split, Contingent Value Right, CK Life Sciences, Non-opioid pain treatment, Nav 1.7 inhibitor